Oryzon Genomics SA
MAD:ORY

Watchlist Manager
Oryzon Genomics SA Logo
Oryzon Genomics SA
MAD:ORY
Watchlist
Price: 1.654 EUR 0.98% Market Closed
Market Cap: 105.5m EUR
Have any thoughts about
Oryzon Genomics SA?
Write Note

EV/EBIT
Enterprise Value to EBIT

-22.7
Current
-23.7
Median
3.8
Industry
Higher than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-22.7
=
Enterprise Value
102m EUR
/
EBIT
-4.5m EUR
All Countries
Close
Market Cap EV/EBIT
ES
Oryzon Genomics SA
MAD:ORY
104.1m EUR -22.7
FR
Pharnext SCA
OTC:PNEXF
6T USD -214 322.8
US
Abbvie Inc
NYSE:ABBV
300.2B USD 22.8
US
Amgen Inc
NASDAQ:AMGN
158.7B USD 33.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
126.8B USD 28.1
US
Gilead Sciences Inc
NASDAQ:GILD
115B USD 10.1
US
Epizyme Inc
F:EPE
94.1B EUR -507.3
AU
CSL Ltd
ASX:CSL
137.3B AUD 25.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
88.3B USD 19.4
US
Seagen Inc
F:SGT
39.3B EUR -53.7
NL
argenx SE
XBRU:ARGX
34.1B EUR -76.1
EBIT Growth
ES
Oryzon Genomics SA
MAD:ORY
Average EV/EBIT: 23.2
Negative Multiple: -22.7
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -214 322.8 N/A
US
Abbvie Inc
NYSE:ABBV
22.8
88%
US
Amgen Inc
NASDAQ:AMGN
33.1
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.1
44%
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -507.3 N/A
AU
CSL Ltd
ASX:CSL
25.9
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.4
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.1 N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-15.2
2-Years Forward
EV/EBIT
-22.6
3-Years Forward
EV/EBIT
-21.2

See Also

Discover More